Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of WXFL10203614 tablets in moderate-to-severe atopic dermatitis
CTR20242982Phase 2Completed
- Sponsor
- Wuxi Fortune Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10203614 in atopic dermatitis (AD), sponsored by Wuxi Fortune Pharmaceutical Co., Ltd.. Started Aug 2024; status: completed.
02
Drugs
WXFL10203614
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20242982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242982.